Addiction news, articles and features | New Scientist /topic/addiction/ Science news and science articles from New Scientist Tue, 20 May 2025 10:30:33 +0000 en-US hourly 1 https://wordpress.org/?v=7.0.1 242057827 Vaccine may treat cocaine addiction by blocking drug’s entry to brain /article/2480576-vaccine-may-treat-cocaine-addiction-by-blocking-drugs-entry-to-brain/?utm_campaign=RSS|NSNS&utm_content=addiction&utm_medium=RSS&utm_source=NSNS Tue, 20 May 2025 14:00:58 +0000 /?post_type=article&p=2480576 2480576 Experimental medication helps treat cocaine addiction /article/2475260-experimental-medication-helps-treat-cocaine-addiction/?utm_campaign=RSS|NSNS&utm_content=addiction&utm_medium=RSS&utm_source=NSNS Mon, 07 Apr 2025 18:30:08 +0000 /?post_type=article&p=2475260 2475260 US government fired researchers running a crucial drug use survey /article/2474698-us-government-fired-researchers-running-a-crucial-drug-use-survey/?utm_campaign=RSS|NSNS&utm_content=addiction&utm_medium=RSS&utm_source=NSNS Tue, 01 Apr 2025 21:15:25 +0000 /?post_type=article&p=2474698 2474698 What do GLP-1 drugs really tell us about the brain’s reward system? /article/2473535-what-do-glp-1-drugs-really-tell-us-about-the-brains-reward-system/?utm_campaign=RSS|NSNS&utm_content=addiction&utm_medium=RSS&utm_source=NSNS Wed, 26 Mar 2025 11:00:00 +0000 http://mg26535364.100 2473535 Microdosing weight-loss drugs is on the rise 鈥 but does it work? /article/2473536-microdosing-weight-loss-drugs-is-on-the-rise-but-does-it-work/?utm_campaign=RSS|NSNS&utm_content=addiction&utm_medium=RSS&utm_source=NSNS Wed, 26 Mar 2025 11:00:00 +0000 http://mg26535364.200

Madison Burgess decided to get serious about weight loss when the scale hit 91 kilograms (200 pounds). She began taking Ozempic. The medication worked better than she ever thought possible: even on the low starter dose, she lost more than 2 kg (5 lbs) within the first week.

Problems began, however, when Burgess, a 25-year-old healthcare administrator from Bloomfield, Michigan, ramped up her intake, as per the manufacturer鈥檚 guidelines. 鈥淭he higher doses were rough on me,鈥 she says. The constipation, nausea, diarrhoea and acid reflux hit hard and made eating difficult. That鈥檚 when she decided to drop back down to a lower dose and determine whether she could continue seeing benefits.

This article is part of a special series investigating the GLP-1 agonist boom. Read more here.

Burgess is just one of a growing number of people who are 鈥渕icrodosing鈥 鈥 a practice more typically associated with psychedelics such as LSD and psilocybin 鈥 by taking lower-than-standard amounts of weight-loss drugs such as Wegovy and Mounjaro (see 鈥淗ow they work鈥, below).

For some, the hope is to avoid side effects while losing weight, while others want to tap into the anti-inflammatory effect of these medications or reap their other benefits for the heart and the brain (see 鈥淎 wonder drug鈥?, below). Microdosing the drugs has even been by ultra-wealthy elites like tech entrepreneur Bryan Johnson, and is rumoured to be the secret weapon of Hollywood stars wanting to look svelte for photo calls.

The question is, does this off-label, low-dose experimentation work?

Medications such as Ozempic, Mounjaro and their ilk come in pre-loaded injectable pens. In conjunction with their healthcare provider, users typically follow a dosing regime that goes up. . In the first month, users take a low introductory dose of 0.25 milligrams a week. This then doubles, and then doubles again until a 鈥渕aintenance鈥 dose of either 1.7 or 2.4 mg per week is achieved, which is then taken long term. These standard doses are the only strengths that have been studied in large-scale clinical trials.

For this reason, microdosing these weight-loss medications isn鈥檛 approved by the US Food and Drug Administration (FDA) or by other health authorities. But that hasn鈥檛 stopped people from trying it, says at the Veterans Affairs St. Louis 午夜福利1000集合 Care System in Missouri.

For Burgess, small doses of between 0.25 and 0.5 mg per week have been a success: she has lost 27 kg (60 lbs) and reached her goal weight without the problematic side effects. 鈥淎t the lower doses, I don鈥檛 have symptoms,鈥 she says. Burgess continues to take the drug to avoid regaining weight 鈥 an additional motivation for microdosing.

Inflammation

Another microdosing enthusiast, , a nurse practitioner who owns her own medical weight-loss practice in Golden, Colorado, says that low doses of tirzepatide have generally improved her quality of life. She takes 2 mg per week (the recommended starter dose is 2.5 mg) and contends that microdosing has reduced her inflammation, as evidenced by her having fewer aches and pains, given her more energy, and generally helped her choose a more wholesome diet. 鈥淗aving less thoughts about food and less cravings makes it much easier to want to choose healthy foods,鈥 says Sorensen.

础濒-础濒测鈥檚 identified a host of health benefits in addition to weight loss for those taking the medications, including a reduced risk of substance use disorders, Alzheimer鈥檚 disease, dementia, clotting disorders and many other conditions. But these were at higher doses and there is no data to show that similar results will occur in those who microdose.

鈥淔or most people, we need higher doses to see weight loss and diabetes results, but there are some exceptions,鈥 says Carolynn Francavilla, an obesity physician in Denver, Colorado. The major clinical trials investigating semaglutide have found a large variability in response. Around , achieving weight loss in excess of 20 per cent; their sensitivity to the medication may mean that it takes far less of it for them to see results.

Longevity

Whether the drugs are indeed a fountain of youth remains unclear, but we do know that they can . 鈥淚t is plausible that microdosing could provide some [anti]inflammatory benefits 鈥 but we just don鈥檛 know yet,鈥 says Al-Aly.

Still, the medications shouldn鈥檛 be taken haphazardly. 鈥淭here should be a medical problem that we鈥檙e improving if we鈥檙e going to use the medications at any dose,鈥 says Francavilla. And it could be dangerous for some people, especially those with , some types of thyroid cancer and some gastrointestinal issues like , a condition that leads to delayed gastric emptying.

In the US, many of those who microdose source their GLP-1 drugs from compounding pharmacies. These provide custom-made medications from pharmaceutical-grade ingredients when the branded medications are in short supply. This is a cheaper option than buying Wegovy and other brands at retail pharmacies, but comes with the risk of contamination and inaccurate dosages, as these injections aren鈥檛 FDA-approved for safety and quality. In the coming months, however, the compounding of semaglutide injections , as there is no longer a shortage of the brand-name versions. This will have knock-on implications for microdosers like Burgess, who had started using compounded injections rather than Ozempic in her bid to avoid regaining weight.

Still, Burgess isn鈥檛 planning to stop microdosing semaglutide anytime soon. 鈥淚t鈥檚 a tool that helped me in my weight-loss journey,鈥 she says.

How they work

Drugs such as semaglutide (sold as Wegovy for weight loss and Ozempic for diabetes), liraglutide (sold as Saxenda and Victoza) and exenatide (sold as Byetta) mimic the actions of glucagon-like peptide-1 (GLP-1). This hormone promotes the feeling of fullness, or satiety, after eating and stimulates insulin production, lowering blood sugar levels.

Overall, this means that these drugs 鈥 technically known as GLP-1 receptor agonists 鈥 reduce hunger levels, leading to reduced energy intake from food and significant weight loss for most people when used long term. Recently, a drug called tirzepatide (sold as Mounjaro and Zepbound) has also come on the market, which mimics GLP-1 plus another satiety hormone, GIP.

A wonder drug?

Semaglutide and other GLP-1 drugs have been linked to a lower risk of a slew of health conditions, not just obesity and diabetes 鈥 but how robust is the evidence?

Heart disease

Strong. by 20 per cent. Approved by the US Food and Drug Administration (FDA) last year to in people who are overweight or obese.

Kidney disease

Strong. by 24 per cent. in people with type 2 diabetes.

Sleep apnea

Strong. Tirzepatide in two placebo-controlled trials.

Alzheimer's disease

Promising. Observational studies show semaglutide is in people with type 2 diabetes, compared with other diabetes medications. are due later this year.

Depression

Promising. Several clinical trials suggest that compared with a placebo or other diabetes treatments. Results of a are due in the next few months.

Eye conditions

Early stage. In observational studies, GLP-1 drugs have been linked to a compared with other diabetes medications, but to an increase in the risk of NAION, a rare form of vision loss.

Pain

Mixed. Semaglutide did better than a placebo at . GLP-1 drugs also increased pain tolerance in mice and have been linked to 鈥 but they may increase discomfort in the abdomen and bones.

Liver disease

Mixed. Semaglutide in one early-stage trial, but . A larger study is .

]]>
2473536
Why do Ozempic and Wegovy seem to treat everything? /article/2456669-why-do-ozempic-and-wegovy-seem-to-treat-everything/?utm_campaign=RSS|NSNS&utm_content=addiction&utm_medium=RSS&utm_source=NSNS Tue, 03 Dec 2024 12:00:22 +0000 /?post_type=article&p=2456669 2456669 Media portrayals peddle a dangerous fiction about substance misuse /article/2445993-media-portrayals-peddle-a-dangerous-fiction-about-substance-misuse/?utm_campaign=RSS|NSNS&utm_content=addiction&utm_medium=RSS&utm_source=NSNS Wed, 04 Sep 2024 18:00:00 +0000 http://mg26335070.100 2445993 We have tools to solve the opioid crisis 鈥 so why aren鈥檛 they used? /article/2444211-we-have-tools-to-solve-the-opioid-crisis-so-why-arent-they-used/?utm_campaign=RSS|NSNS&utm_content=addiction&utm_medium=RSS&utm_source=NSNS Thu, 15 Aug 2024 21:26:32 +0000 /?post_type=article&p=2444211 2444211 Ozempic and Wegovy could help people quit smoking /article/2441769-ozempic-and-wegovy-could-help-people-quit-smoking/?utm_campaign=RSS|NSNS&utm_content=addiction&utm_medium=RSS&utm_source=NSNS Mon, 29 Jul 2024 21:00:27 +0000 /?post_type=article&p=2441769
Ozempic could treat many more conditions than just type 2 diabetes and obesity
myskin/Shutterstock
Another study adds credence to the idea that semaglutide 鈥 the drug in medications such as Ozempic and Wegovy 鈥 could help treat addiction. Researchers found that people who were prescribed the drug for type 2 diabetes were then less likely to seek medical care for tobacco use than those taking other diabetes medications. Semaglutide helps treat obesity and type 2 diabetes by mimicking a hormone that reduces appetite and regulates blood sugar levels. Previous research has also linked it to lower rates of cannabis use disorder and alcoholism.听 To learn about semaglutide鈥檚 effect on tobacco addiction, at Case Western Reserve University in Ohio and her colleagues collected data from electronic health records on nearly 223,000 people in the US with type 2 diabetes and tobacco addiction. Nearly 6000 of them had been prescribed semaglutide, while the rest used one of seven other diabetes medications. The researchers then tracked whether the individuals met with a healthcare provider for any tobacco use or received smoking cessation medications or counselling within a year of starting the medications.听 After accounting for variables such as age, sex, race and certain health conditions, the team found that those using semaglutide were less likely to receive any form of tobacco-related healthcare, on average, than those taking other medications. The researchers took this as a probable indication that these individuals had been more successful at quitting smoking. For instance, semaglutide users were 32 per cent less likely to receive this care than insulin users and 18 per cent less likely than metformin users.听
It could be that people who take semaglutide are less likely to seek medical care for their tobacco use without having necessarily abstained from such products. But Xu says that all the individuals sought tobacco-related healthcare at similar rates before starting their type 2 diabetes medications, so semaglutide may actually have been helpful. This study wasn鈥檛 a randomised-controlled trial, which is the best form of medical evidence, and so these findings don鈥檛 definitively show that semaglutide is behind the effect, says at Pennsylvania State University. Still, other research shows semaglutide reduces activity in brain regions involved with reward processing and cravings, so it is possible that there could be some causal connection.
Journal reference:

Annals of Internal Medicine

]]>
2441769
The surprising mental health and brain benefits of weight-loss drugs /article/2435246-the-surprising-mental-health-and-brain-benefits-of-weight-loss-drugs/?utm_campaign=RSS|NSNS&utm_content=addiction&utm_medium=RSS&utm_source=NSNS Wed, 12 Jun 2024 15:00:00 +0000 http://mg26234953.900 2435246